|Line 46:||Line 46:|
LSZ, also known as Lysergic acid 2,4-dimethylazetidide, is a hallucinogenic drug and an analogue of LSD developed by the team led by David E. Nichols at Purdue University. While LSZ has subtly different effects than LSD, it appears to be slightly longer lasting and slightly more potent.
While LSZ has subtly different effects than LSD, with a slightly shorter duration while also having a longer comeup.
While widespread use of LSZ is relatively new and therefore its full impact is unknown, it is likely that it has a similar safety profile to LSD. Refer to LSD and Psychedelic Harm Reduction for more information.
Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption.